Rapid Therapy Guidance for Patients Seeking New Options

Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer cells. We have developed a rapid therapy guidance test that enables oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.

About Us

Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT).

What’s New at Travera 

Read our white paper

The purpose of this white paper is to provide an overview of how therapies are selected for cancer patients and explain the current challenges of precision medicine and points to a promising future for personalizing cancer therapies.

Travera’s solution is to try drugs on the OUTSIDE of the patient rather than INSIDE. That is, remove some of the cancer cells from the patient and apply the drugs to these removed (“ex vivo”) cancer cells. We can then try many different cancer drugs (in very small quantities) against these cancer cells. This approach completely eliminates toxicity, dramatically reduces the cost (because we only need enough drug to treat a few cells, not a whole person), and only takes a couple of days.


Click here to download the white paper

Patient Testimonial


“While the introduction of several novel agents and regimens for newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma has improved outcomes, it has also increased the complexity of treatment selection since not all patients respond. Having a test that can prospectively assess an individual’s personalized response is a much needed breakthrough for patients with multiple myeloma.”

Jack Aiello

Patient advocate and multiple myeloma survivor